Immunomodulatory therapy, risk factors and outcomes of hospital-acquired bloodstream infection in patients with severe COVID-19 pneumonia: a Spanish case–control matched multicentre study (BACTCOVID)Original Article Published on 2021-07-072022-11-01 Journal: Clinical microbiology and infection : the official [Category] COVID-19, MERS, [키워드] 1:1 Abstract accounted acute respiratory distress Admission age Analysis Bacteraemia bloodstream BSI caused characteristics of patient Cohort combinations Control Corticosteroids COVID-19 database Enterococcus hazard ratio Hospital-acquired infection Hospitalized hospitalized patient identify Image immunomodulatory drug immunomodulatory therapy in-hospital mortality increased risk Infection IQR median time mortality risk multicentre objective outcome Patient patients patients with COVID-19 performed polymicrobial infection prospective cohort Pseudomonas aeruginosa Result risk risk factor SARS-CoV-2 pneumonia severe COVID-19 Severe COVID-19 pneumonia severity Sex Spanish syndrome therapy time factor Tocilizumab was performed with COVID-19 [DOI] 10.1016/j.cmi.2021.06.041 PMC 바로가기 [Article Type] Original Article
Tocilizumab in COVID-19: Factors Associated With Mortality Before and After TreatmentPharmacology Published on 2021-07-012022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] 95% CI addition Administered administration age Analysis average baseline C-reactive protein Cohort Comorbidity COVID-19 COVID-19 diagnosed patient Cox regression model death Deceased Diabetes Mellitus Diagnosis discharged discharged patients early treatment Factor had more hazard hospitalized patient Immunosuppression immunosupression laboratory parameter Laboratory parameters lactate dehydrogenase lymphocyte Mortality neutrophil PaO Patient Platelet predictor receiving risk risk factor risk of death SARS-CoV-2 pneumonia TCZ the mean Tocilizumab Treatment troponin I variable were used with COVID-19 [DOI] 10.3389/fphar.2021.620187 PMC 바로가기 [Article Type] Pharmacology
[Low dose radiotherapy for COVID-19 pneumopathy: Biological rationale and literature review][COVID-19 폐렴에 대한 저선량 방사선 치료: 생물학적 근거 및 문헌 고찰]Review Published on 2021-07-012022-09-11 Journal: Cancer radiothérapie : journal de la Société franç [Category] 임상, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-inflammatory activity anti-inflammatory properties anti-inflammatory property Antibiotics Bacterial Biological clinical presentation Clinical presentations clinical trial Controlled trial coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 demonstrated dose English Entire lung explain Faible dose feasibility forme French greater in vitro in vitro data in vivo less low dose low-dose lung Lung disease Mortality over pandemic Pathologies Patient pneumopathy Radiobiologie radiobiology Radiothérapie Radiotherapy Randomized Randomized controlled trial report risk SARS-CoV-2 SARS-CoV-2 pneumonia severe acute respiratory syndrome Coronavirus therapy Treatment Trial [DOI] 10.1016/j.canrad.2021.03.005 PMC 바로가기 [Article Type] Review
Protracted SARS-CoV-2 pneumonia with rituximab treatment: About two cases리툭시맙 치료를 받은 지속성 SARS-CoV-2 폐렴: 약 2건Case Reports Published on 2021-07-012022-09-11 Journal: Journal of medical virology [Category] SARS, 바이오마커, 진단, [키워드] SARS-CoV-2 pneumonia [DOI] 10.1002/jmv.26921 PMC 바로가기 [Article Type] Case Reports
Subcutaneous Emphysema and Pneumomediastinum Following Non-invasive Ventilation in a Patient With Severe COVID-19 DiseaseInternal Medicine Published on 2021-06-302022-10-31 Journal: Cureus [Category] COVID-19, [키워드] acute respiratory syndrome caused Complication coronavirus COVID-19 Early detection etiology Factor fatal complication healthy high mortality rate incidence Invasive mechanical ventilation Lung injury male mechanical ventilation NIMV Non-invasive non-invasive ventilation observation outcome Pathogenesis Patient Pneumomediastinum positive potential risk receiving SARS-CoV-2 SARS-CoV-2 pneumonia severe coronavirus disease Subcutaneous subcutaneous emphysema tested treated while [DOI] 10.7759/cureus.16051 PMC 바로가기 [Article Type] Internal Medicine
Obesity May Not Be Associated with 28-Day Mortality, Duration of Invasive Mechanical Ventilation and Length of Intensive Care Unit and Hospital Stay in Critically Ill Patients with Severe Acute Respiratory Syndrome Coronavirus-2: A Retrospective Cohort StudyObservational Study Published on 2021-06-292022-10-04 Journal: Medicina [Category] MERS, SARS, 임상, [키워드] 28-day mortality age all-cause mortality assessment association body mass index correlation critically ill patients Duration Factor failure had no hospital Hospital stay ICU Ill independent intensive care unit Invasive mechanical ventilation investigated Kaplan–Meier Length Length of stay log rank material Mechanical multivariate Cox regression obesity Observational cohort study Patient Pneumonia respiratory retrospective RT-PCR SARS-CoV-2 SARS-CoV-2 pneumonia severe acute respiratory syndrome coronavirus-2 significant difference SOFA statistically significant survival the patient [DOI] 10.3390/medicina57070674 PMC 바로가기 [Article Type] Observational Study
Compromised Lung Volume and Hemostatic Abnormalities in COVID-19 Pneumonia: Results from an Observational Study on 510 Consecutive PatientsArticle Published on 2021-06-292022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] abnormality adjusted Admission affected Autopsy BMI Chest CT clinical clinically Compromised consecutive patient correlation COVID-19 cross-sectional CRP CT scan D-dimer D-dimer level described diagnosed with COVID-19 evaluate fibrinogen greater Hemostasis Hemostatic hospital independent predictor lung lung damage Lung injury lung involvement lung volume measurements males median Odds ratio Patient Platelet Pneumonia pulmonary microthrombosis Quantitative regression analysis Result retrieved retrospective SARS-CoV-2 pneumonia severity thromboembolic complications Via Volume was used with COVID-19 [DOI] 10.3390/jcm10132894 PMC 바로가기 [Article Type] Article
Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey파비피라비르를 사용한 SARS-CoV-2 폐렴 치료: 터키 Ege University 코호트의 초기 결과Article Published on 2021-06-282022-09-10 Journal: Turkish Journal of Medical Sciences [Category] MERS, SARS, 치료제, [키워드] antiviral therapy baseline Cohort coronavirus Course COVID-19 diagnosed with COVID-19 died discharged distress Favipiravir full recovery hospital ICU improvement information intensive care intensive care unit Laboratory majority material pandemic Patient patients Pneumonia provide required respiratory distress Result retrospective Safe SARS-CoV-2 SARS-CoV-2 pneumonia severe pneumonia severe SARS severe SARS-CoV-2 Side effect Treatment Turkey university [DOI] 10.3906/sag-2008-33 PMC 바로가기 [Article Type] Article
Long-Term Pulmonary Damage From SARS-CoV-2 in an Infant With Brief Unexplained Resolved Events: A Case ReportMedicine Published on 2021-06-112022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] acute respiratory syndrome administration age breathing Chest computed tomography coronavirus COVID-19 COVID-19 infection damage died distress Fever FIVE Follow-up healthy Hospital admission Hospitalized Infant infected with SARS-CoV-2 Inhaled lack lung involvement mild respiratory mother Nasopharyngeal swab Newborn over oxygen Pneumonia positive pulmonary pulmonary complication pulmonary involvement report required resolved respiratory symptom SARS-CoV-2 SARS-CoV-2 pneumonia severe pneumonia sleep disorders tested weakness [DOI] 10.3389/fmed.2021.646837 PMC 바로가기 [Article Type] Medicine
Clinical Course and Risk Factors for In-Hospital Mortality of 205 Patients with SARS-CoV-2 Pneumonia in Como, Lombardy Region, ItalyArticle Published on 2021-06-112022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] age Analysis analyzed Anticoagulant anticoagulation Antiviral antiviral drugs antiviral therapy C-reactive protein Characteristics clinical clinical risk factor Comorbidities Coronavirus disease 2019 Course COVID-19 COVID19 CRP disease drug Effectiveness elevated Factor greater Hydroxychloroquine In-hospital death in-hospital mortality infected with SARS-CoV-2 inhibitors interleukin-6 Intervention Italy Laboratory laboratory-confirmed lactate dehydrogenase LDH less lombardy management Mortality Multivariable regression multivariate logistic regression Older outbreak P/F ratio pathway Patient patients treated Pneumonia prognostic reduction in mortality Region Result risk factor Risk factors SARS-CoV 2 SARS-CoV-2 SARS-CoV-2 pneumonia significant effect single-center Steroids supportive care tested therapy Tocilizumab tocilizumab therapy treat Treatment treatment strategy [DOI] 10.3390/vaccines9060640 PMC 바로가기 [Article Type] Article